(α4)3(β2)2 | (α4)2(β2)3 | (α4)2(β2)2α5 | α7 | |
---|---|---|---|---|
nM | ||||
Nicotine | 56 ± 16 | 15 ± 5 | 17 ± 7 | 1000 ± 380 |
Cytisine | 27 ± 14 | 8 ± 5 | 3.2 ± 1.6 | 1200 ± 570 |
Varenicline | 2.8 ± 1.3 | 1.6 ± 0.5 | 3.3 ± 0.9 | 334 ± 140 |
3-pyr-Cyt | 16,000 ± 12,000 | 600 ± 500 | 2300 ± 1000 | N.A. |
GTS-21 | 1000 ± 400 | 170 ± 100 | 1300 ± 475* | |
S 24795 | 36,000 ± 7000 | 53,000 ± 6000 | 15,000 ± 4000* |
N.A., not available.
↵* Inhibition after a phase of potentiation.